Brii Biosciences Appoints Coy Stout as Senior Vice President of U.S. Market Access and Patient Advocacy

DURHAM, N.C. and BEIJING, Sept. 28, 2021 /PRNewswire/ -- Brii Biosciences Co., Ltd.Brii Biosciences (Stock Code: 2137.HK, hereinafter referred to as “Brii Biosciences” or the “Company”), a multinational company dedicated to developing innovative therapies for unmet medical needs and major public health diseases, today announced the appointment of Coy Stout as Senior Vice President, Head of U.S. Market Access and Patient Advocacy. Mr. Stout brings over 25 years of leadership experience in the public health and biopharmaceutical industries. Through the development of strategic commercial plans and the establishment of key infrastructure, he has facilitated rapid access to critical therapies for U.S. patients across a wide range of disease areas, particularly for infectious diseases.

“As we rapidly advance the regulatory filing in the United States for the BRII-196/BRII-198 combination monoclonal antibody therapy for the treatment of COVID-19, in preparation for our next phase of development, Coy will become an indispensable member of our leadership team,” said Dr. Zhi Hong, Chief Executive Officer of Brii Biosciences. “Coy brings extensive experience in market access and reimbursement strategies for a wide range of infectious disease products. Furthermore, his passion for public health and patient care will help us establish a successful commercial platform to deliver our COVID-19 antibody therapy to more patients in urgent need.”

Prior to joining Brii Biosciences, Mr. Stout served as Vice President of U.S. Commercial and Market Access, responsible for managing Gilead Sciences’ key federal business. During his 17-year tenure, he held key leadership positions at Gilead, including overseeing commercial and market access, and worked closely with government affairs and policy teams to inform product planning initiatives. In addition to his experience in drug coverage, innovative payment models, and patient support programs, Mr. Stout led market access and commercialization efforts for the launch of over 30 products. As a lifelong advocate for patient care, he also holds a social work certification and has managed teams in community settings, dedicating his efforts to supporting patients living with HIV/AIDS.

“Brii Biosciences is at an exciting stage of development, and I am thrilled to join the company during this phase. I look forward to leveraging my deep industry expertise and passion for healthcare to establish a comprehensive commercialization plan for BRII-196/BRII-198 and future products,” said Coy Stout, Senior Vice President and Head of U.S. Market Access and Patient Advocacy at Brii Biosciences.

For more information about Brii Biosciences and its leadership team, please visit the official website.www.briibio.com。

About Brii Biosciences

Brii Biosciences Limited (“Brii Biosciences” or the “Company”; Stock Code: 2137.HK) is a biotechnology company based in China and the United States, dedicated to developing innovative therapies for major infectious diseases in China and globally (such as hepatitis B, human immunodeficiency virus (HIV) infection, and multidrug-resistant (MDR) or extensively drug-resistant (XDR) Gram-negative bacterial infections) as well as other diseases posing a significant public health burden (such as central nervous system (CNS) diseases). For more information, please visitwww.briibio.com。

Media Inquiry:
media@briibio.com 
Summer Li(China)
+86-135-2191-1607
Darcie Robinson(United States)
+1-203-919-7905

Investor Inquiries:
ir@briibio.com 
Chris Fang
+86-139-1692-8049